Filtry
Treatment of patients with recurrent/refractory aggressive non-Hodgkin's lymphoma: effectiveness and safety of pixantrone
with substantial risk of cardiotoxicity. Pixantrone is anthracycline-like cytostatic, pixantrone monotherapy was approved by the European Medicines Agency (EMA) for the treatment of adults with multiply relapsed or refractory aggre...
FD - Onkologie a hematologie
- 2016 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Pixantrone in the treatment of non-Hodgkin lymphoma
Pixantrone is a novel aza-anthracenedione developed with aim of reducing cardiac toxicity whilst preserving the efficacy of anthracyclines. Pixantrone acts anthracycline pixantrone has reduced potential for the production o...
Oncology
- 2017 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Pixantrone in the treatment of non-Hodgkin lymphoma
Pixantrone is a novel aza-anthracenedione developed with aim of reducing cardiac toxicity whilst preserving the efficacy of anthracyclines. Pixantrone acts anthracycline pixantrone has reduced potential for the production o...
Oncology
- 2017 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m to six cycles. Pixantrone has a conditional ...
FD - Onkologie a hematologie
- 2016 •
- Jx •
- Odkaz
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Report of University Hospital Ostrava to the clinical trial protocol: PIX306
A Randomized, Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for...
FD - Onkologie a hematologie
- 2016 •
- Vsouhrn
Rok uplatnění
Vsouhrn - Souhrnná výzkumná zpráva
Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PIX306
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for ...
FD - Onkologie a hematologie
- 2016 •
- Vsouhrn
Rok uplatnění
Vsouhrn - Souhrnná výzkumná zpráva
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized
for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m2 (5.2-8.4) with pixantrone + rituximab (PIX + R) and 6.3 months (4.4-8.1......
Hematology
- 2020 •
- Jimp •
- Odkaz
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
- 1 - 7 z 7